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Abstract
Secreted growth factors have been shown to stimulate the transcriptional activity of estrogen receptors (ER) that are
responsible for many biological processes. However, whether these growth factors physically interact with ER remains
unclear. Here, we show for the first time that connective tissue growth factor (CTGF) physically and functionally associates
with ER. CTGF interacted with ER both in vitro and in vivo. CTGF interacted with ER DNA-binding domain. ER interaction
region in CTGF was mapped to the thrombospondin type I repeat, a cell attachment motif. Overexpression of CTGF
inhibited ER transcriptional activity as well as the expression of estrogen-responsive genes, including pS2 and cathepsin D.
Reduction of endogenous CTGF with CTGF small interfering RNA enhanced ER transcriptional activity. The interaction
between CTGF and ER is required for the repression of estrogen-responsive transcription by CTGF. Moreover, CTGF reduced
ER protein expression, whereas the CTGF mutant that did not repress ER transcriptional activity also did not alter ER protein
levels. The results suggested the transcriptional regulation of estrogen signaling through interaction between CTGF and ER,
and thus may provide a novel mechanism by which cross-talk between secreted growth factor and ER signaling pathways
occurs.
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Introduction
Estrogen receptors (ERa and ERb), hormone-dependent
transcription factors belonging to the steroid/thyroid-hormone-
receptor superfamily, play important roles in the development and
progression of steroid hormone-dependent cancers, including
breast cancer, ovarian cancer and cervical cancer [1,2]. ERs
share structural similarity characterized by several functional
domains. N-terminal estrogen-independent and C-terminal estro-
gen-dependent activation function domains (AF1 and AF2,
respectively) contribute to the transcriptional activity of the two
receptors. The DNA binding domain (DBD) of the ERs is centrally
located. The ligand binding domain, overlapping AF2, shows 58%
homology between ERa and ERb. The DBD is identical between
the two receptors except for three amino acids. However, the AF1
domain of ERb has only 28% homology with that of ERa ERa
and ERb have similar binding affinities for estrogen and their
cognate DNA binding site, which is probably due to the high
degree of sequence homology they share in their ligand and DNA
binding domains.
Traditionally, ERs are thought to be intracellular transcription
factors that bind to the promoters of the estrogen-responsive target
genes, such as pS2 and cathepsin D [3]. Recently, estrogen was
shown to mediate rapid non-genomic pathyways through
interaction with membrane receptors, especially membrane ERs
[4,5]. Membrane ERs also play an important role in indirect
regulation of ER transcriptional activity. Membrane ERa-
mediated non-genomic estrogen actions require a large protein
complex, comprising ERa, the adaptor protein Shc and insulin-
like growth factor 1 receptor (IGF-1R).
Estrogens, acting via ER, are important regulators of the growth
and differentiation of many estrogen-regulated tissues, including
ovary, uterus, mammary gland, and brain. Secreted growth
factors, such as epidermal growth factor (EGF) and insulin-like
growth factor-1 (IGF-1), also mimic estrogens in their ability to
increase ER transcriptional activity as well as the expression of ER
target genes [6,7]. EGF and IGF-1 exerts some of their biological
responses in an ER-dependent manner, suggesting the cross-talk of
growth factors with ER signaling pathway. However, whether
these growth factors physically interact with ER remains unclear.
In this study, we have identified and characterized a novel ER-
interacting protein, connective tissue growth factor (CTGF).
CTGF is a secreted protein that belongs to the CCN family,
including Cyr61 (cysteine-rich protein 61), CTGF, Nov (nephro-
blastoma overexpressed), WISP-1 (Wnt-1-induced secreted protein
1), WISP-2, and WISP-3 [8–10]. CTGF consists of four domains
from the N-terminus to the C-terminus: the insulin-like growth
factor binding protein domain (IGFBP), the Von Willebrand
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(TSP-1) and the C-terminal domain (CT). The biological
properties of CTGF involve cell adhesion, migration, proliferation,
survival, differentiation and tumorigenesis [11]. Here, we show
that CTGF physically interacts with ERa and ERb, and
functionally inhibits ER-mediated estrogen signaling.
Materials and Methods
Plasmids
The reporter constructs ERE-Luc [12], pS2-Luc [12], ARE-Luc
[13] and pFC31-Luc [14], eukaryotic expression vectors for ERa
and ERb [15], prokaryotic expression vectors for glutathione S-
transferase (GST)-tagged ERa,E R a(180–282) and ERb [13–15],
and the yeast expression vectors pAS2-ERb(1–167), pAS2-
ERb(131–324) and pAS2-ERb(286–530) [15] have been described
previously. The yeast expression vectors pAS2-ERa(1–185), pAS2-
ERa(180–282) and pAS2-ERa(282–595) were generated by
inserting the corresponding cDNA fragments into pAS2-1
(Clontech). FLAG-tagged CTGF and its mutants were created
by cloning the corresponding sequences into a pcDNA3 vector
(Invitrogen) linked with FLAG at the carboxyl terminus. Plasmids
encoding GST-CTGF and its mutants were prepared by cloning
the corresponding sequences into pGEX-KG (Amersham Phar-
macia Biotech). His-tagged CTGF and Nov were generated by
inserting the corresponding cDNAs into pET28a (Novagen).
Yeast two-hybrid assay
The bait plasmid pAS2-ERb(131–324) and a human mammary
cDNA prey library (Clontech) were sequentially transformed into
Saccharomyces cerevisiae strain CG1945 according to the
manufacturer’s protocol (Clontech). Transformants were grown
on synthetic medium lacking tryptophan, leucine and histidine but
containing 1 mM 3-aminotriazole. The candidate clones were
rescued from the yeast cells and re-transformed back to the same
yeast strain to verify the interaction between the candidates and
the bait. The unrelated bait plasmid pAS2-lamin C was used as a
negative control.
GST pull-down assay
The GST- and His-fusion proteins were expressed and purified
according to the manufacturers’ protocols (Amersham Pharmacia
and Qiagen). The purified GST fusion protein bound to
glutathione-Sepharose beads were incubated with
35S-labeled in
vitro translation products or purified His-fusion proteins, and the
adsorbed proteins were analyzed as previously described [16].
Coimmunoprecipitation
Cell lysates were prepared in lysis buffer (50 mM Tris at
pH 8.0, 500 mM NaCl, 0.5% Nonidet P-40, 1 mM dithiothreitol,
and protease inhibitors) and mixed with conditioned media. The
mixture was subjected to immunoprecipitation with anti-FLAG
agarose beads (Sigma-Aldrich) as previously described [16].
Immunoblot analysis was performed with anti-ERa (Santa Cruz
Biotech) or anti-ERb (Abcam).
Enzyme-linked immunosorbent assay (ELISA) for protein-
protein binding
The 96-well plates were coated with mouse anti-human CTGF
monoclonal antibody (Santa Cruz Biotech) diluted in 100 mM
carbonate buffer at pH 9.6 (1:1000 v/v) overnight at 4uC. The
wells were washed with PBST (0.05% Tween-20, PBS pH 7.5)
and blocked with PBSTM (0.05% Tween-20, 5% dried milk, PBS
pH 7.5) for 1 h at room temperature. Cell lysates together with
conditioned media were then incubated in wells for 2 h. After
washes with PBST, rabbit anti-human ERa antibody (Sigma-
Aldrich) (1:2500 v/v) or normal rabbit serum (Santa Cruz Biotech)
diluted in PBSTM was incubated in wells for 1 h. Following
washes with PBST, the wells were incubated with HRP-
conjugated goat anti-rabbit IgG (1:2500 v/v) (Santa Cruz Biotech).
After final washes with PBS, 50 ml of TMB reagent (Sigma-
Aldrich) was added. After 30 minutes the reaction was stopped
with 50 ml1MH 2SO4. Absorbance at 415 nm was measured
with a plate reader.
Immunofluorescence assay
Cells on glass coverslips were fixed with 1.6% paraformalde-
hyde for 30 minutes, permeabilized with 0.2% Triton X-100 for
5 minutes, and blocked in 1% normal goat serum for 1 hour. The
coverslips were then incubated with rabbit anti-ERa (Sigma-
Aldrich) or mouse anti-CTGF (Santa Cruz Biotech), followed by
incubation with goat anti-rabbit IgG (Santa Cruz Biotech) or goat
anti-mouse IgG (Santa Cruz Biotech) secondary antibodies. Nuclei
were counterstained with 0.2 mg/ml DAPI. Confocal images were
collected using a Radiance2100 confocal microscope (Bio-Rad).
Luciferase reporter assay
MCF7, ZR75-1 and Hela cells were routinely grown in DMEM
(Invitrogen) supplemented with 10% fetal bovine serum (FBS). For
transfection, cells were seeded in 12- or 24-well plates containing
phenol red-free DMEM medium supplemented with 10%
charcoal-stripped FBS (Hyclone). The cells were transfected using
Lipofectamine 2000 (Invitrogen) with 0.1 or 0.2 mg of the
luciferase reporter ERE-Luc or pS2-LUC plus various amounts
of expression vector for CTGF or recombinant human CTGF,
EGF or IGF-1 proteins (ProSpec), with or without 25 ng or 50 ng
of ERa or ERb expression vector. b-galactosidase reporter was
used as an internal control. After treatment with 10 nM of 17b-
estradiol (E2) for 24 h, the transfected cells were collected.
Luciferase activity was assessed as described [17].
RNA interference
The target sequences for differential knockdown of CTGF
protein expression are GAAGAACATGATGTTCATC (siRNA1)
and GTACCAGTGCACGTGCCTG (siRNA2), respectively.
The target sequences were cloned into pSilencer2.1-U6neo
according to the manufacturer’s protocol (Ambion). Plasmid
pSilencer2.1-U6neo negative control was used as a negative
control vector. Transfection of the plasmid-based siRNAs into
mammalian cells was carried out using Lipofectamine 2000
(Invitrogen). Knockdown of CTGF protein was confirmed by
Western blotting with anti-CTGF (Santa Cruz Biotech).
Stable transfection of CTGF
MCF7 cells were transfected with FLAG-tagged CTGF or
empty vector using Lipofectamine 2000 (Invitrogen), and the
transfected MCF7 cells were selected in 500 mg/ml G418
(Invitrogen) for approximately 2 months. Pooled clones or
individual clones were screened by immunoblot with anti-FLAG
(Sigma-Aldrich). Similar results were obtained with individual
clones or pooled clones.
Electrophoretic mobility shift assay (EMSA)
The ERE (59-AGCTCTTTGATCAGGTCACTGTGACCT-
GACTTT-39) or mutant ERE (EREM; 59-AGCTCTTTGAT-
CAGTACACTGTGACCTGACTTT-39) probes were labeled
CTGF Modulation of ER Activity
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manufacturer. EMSA was performed using LightShift Chemilu-
minescent EMSA kits (Pierce). Briefly, binding reactions contain-
ing 10 mg of nuclear extracts and 1 nmol of oligonucleotide were
performed for 30 min in binding buffer (2.5% glycerol, 0.05%
Nonidet P-40, 50 mM KCl, 5 mM MgCl2, 1 mM EDTA, 10 mM
Tris, pH 7.6, and 50 ng of poly(dI-dC)). Protein-nucleic acid
complexes were resolved using a nondenaturating polyacrylamide
gel consisting of 6% acrylamide, and transferred to a nylon
membrane. The membrane was incubated in blocking solution
followed by incubation with streptavidin-peroxidase. After exten-
sive washing, signal was detected with chemiluminescence
solution.
Real-time RT-PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen) and
reverse transcribed using SuperScript II Reverse Transcriptase
(Invitrogen). Real-time PCR was performed with ERa-, CTGF-,
GAPDH-, and b-actin-specific primers. The sense primer for ERa
was 59-CCACCAACCAGTGCACCATT-39 and the antisense
primer was 59-GGTCTTTTCGTATCCCACCTTTC-39. For
CTGF, the sense primer was 59-GCAGGCTAGAGAAGCA-
GAGC-39 and the antisense primer was 59-ATGTCTT-
CATGCTGGTGCAG-39. The sense primer for GAPDH was
59-ACCACAGTCCATGCCATCAC-39 and the antisense primer
was 59-TCCACCACCCTGTTGCTGTA-39. For b-actin, the
sense primer was 59-ATCACCATTGGCAATGAGCG-39 and
the antisense primer was 59-TTGAAGGTAGTTTCGTGGAT-
39. The fold change in expression of ERa or CTGF was calculated
using the 2
2DDCt method, with GAPDH or b-actin as an internal
control.
Western blot
Approximately 50 mg of protein samples were separated by
SDS-polyacrylamide gel electrophoresis and blotted to a nitrocel-
lulose membrane. Blotted membranes were blocked overnight at
4uC in TBST containing 5% nonfat milk. Blots were incubated
with primary antibodies diluted in TBST containing 5% nonfat
milk for 1 h at room temperature. After washing extensively with
TBST, membranes were incubated with the appropriate horse
radish peroxidase-conjugated secondary antibody (Santa Cruz
Biotech), followed by chemiluminescent detection according to the
manufacturer’s instructions (Pierce). The primary antibodies used
in this study are as follows: mouse anti-FLAG (Sigma-Aldrich),
mouse anti-His (GE Healthcare), rabbit anti-ERa (Santa Cruz
Biotech), rabbit anti-ERb (Abcam), mouse anti-CTGF (Santa
Cruz Biotech) and rabbit anti-GAPDH (Santa Cruz Biotech).
Statistical analysis
The values are expressed as means 6 SD. Statistical significance
in the luciferase activity experiments between two constructs was
assessed by Student’s t-test. When doses and increasing concen-
trations were compared, statistical significance was determined by
one-way analysis of variance (ANOVA). A P value,0.05 was
considered statistically significant.
Results
Interaction of CTGF with ERa and ERb in yeast cells
To identify proteins that could be involved in regulation of
estrogen signaling, we screened a human mammary cDNA library
using amino acids 131–324 containing the ERb DBD and hinge
domains as bait in the yeast two-hybrid system. CTGF was
identified as an ERb-interacting protein. As shown in Fig. 1A,
transformation of yeast cells with CTGF and ERb(131–324), but
not with other control plasmids, activate the his (growth) and lacZ
(b-gal) reporter genes. CTGF did not interact with ERb(1–167)
containing the AF1 and ERb(286–530) containing the AF2
(Fig. 1B), suggesting the specific interaction of CTGF with
ERb(131–324).
Since CTGF specifically interacts with ERb DBD and hinge
domains, and the DBD of ERb has 96% homology with that of
ERa, the possibility that the DBD of ERa may bind to CTGF was
determined by yeast two-hybrid experiments. As shown in Fig. 1C,
the ERa(180–282) containing the DBD specifically interacted with
CTGF, but the ERa(1–185) containing the AF1 and the
ERa(282–595) containing the hinge and AF2 regions did not.
Taken together, these data suggest that the ER DBD domain is
sufficient for CTGF binding in yeast cells.
Figure 1. Identification and characterization of the CTGF-ER
interaction in yeast cells. (A) Identification of CTGF as an ERb-
interacting protein by the yeast two-hybrid system. Yeast CG1945 cells
were transformed with the indicated plasmids (bait and prey) and
grown on SD/-Trp-Leu and SD/-Trp-Leu-His. Colonies grown on SD/-Trp-
Leu or SD/-Trp-Leu-His were tested for b-galactosidase activity (LacZ).
Positive interaction is indicative of His- (growth) and LacZ- (b-gal)
positive colonies. (B) Mapping of the CTGF interaction region in ERb.
CG1945 cells were transformed with the indicated constructs and
analyzed as in (A). Schematic diagram of the ERb protein is shown at the
top. (C) Mapping of the CTGF interaction region in ERa. CG1945 cells
were transformed with the indicated plasmids and analyzed as in (A).
Schematic diagram of the ERa protein is shown at the top.
doi:10.1371/journal.pone.0020028.g001
CTGF Modulation of ER Activity
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20028Interaction of CTGF with ERa and ERb in mammalian cells
and in vitro
To further confirm the interaction between CTGF and ERa/
ERb, coimmunoprecipitation experiments were performed with
MCF7 breast cancer cells. FLAG-tagged CTGF coimmunopreci-
pitated ERa and ERb (Fig. 2A). Since CTGF is expressed at
relatively low level in ERa-positive cell lines, such as MCF7
(approximately 15 ng/10
7 cells/24 h determined by ELISA) and
ZR75-1 (approximately 12 ng/10
7 cells/24 h) breast cancer cell
lines (data not shown), a sensitive ELISA-based protein-protein
binding detection method was employed to determine interaction
of endogenous CTGF with endogenous ERa. As shown in Fig. 2B,
endogenous CTGF specifically interacted with endogenous ERa
in MCF7 cells. Moreover, immunofluorescence analysis of MCF7
cells showed that endogenous CTGF protein colocalized with
endogenous ERa protein in both the cytoplasm and the
membrane (Fig. 2C). The specificity of mouse anti-CTGF was
confirmed by pre-incubation of the primary antibody with His-
tagged CTGF protein or His control (Fig. S1A). Detection of
CTGF was completely blocked by pre-incubating anti-CTGF with
His-CTGF fusion protein but not by pre-incubating with His
control. Furthermore, the staining pattern of endogenous CTGF
in MCF7 cells was similar to that of FLAG-tagged CTGF fusion
protein (Fig. S1B).
Figure 2. CTGF interacts with ERa and ERb in mammalian cells and in vitro. (A) Interaction of CTGF with ERa and ERb in mammalian cells.
MCF7 cells were transfected with expression vector for FLAG-tagged CTGF (CTGF-FLAG) or empty (FLAG) plasmid in the presence of 17b-estradiol
(E2). Conditioned medium from the FLAG- or CTGF-FLAG-transfected cells was incubated with MCF7 cell lysates. Immunoprecipitation (IP) was
performed using anti-FLAG monoclonal antibody, and immunoblotted (IB) with anti-ERb or anti-ERa. (B) Physiological interaction of CTGF with ERa by
ELISA. CTGF monoclonal antibody-coated wells were incubated with MCF7 cell lysates together with conditioned media, followed by incubation with
rabbit anti-human ERa antibody or normal rabbit serum. Absorbance at 415 nm (OD value) was measured with a plate reader. (C) Colocalization of
endogenous CTGF with ERa. MCF7 cells were treated with 10 nm E2, immunostained for CTGF (green) and ERa (red), and counterstained for DNA
with DAPI (blue). The images were captured by confocal immunofluorescence microscopy; original magnification, 6100. (D) Direct interaction of
CTGF with ERa and ERb. Glutathione–Sepharose beads bound with GST-ERa/ERb or with GST were incubated with purified His-tagged CTGF or Nov.
After washing the beads, the bound proteins were subjected to SDS–PAGE and Western blot with anti-His antibody.
doi:10.1371/journal.pone.0020028.g002
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ERb in vitro, GST pull-down experiments were performed in
which purified GST-ERa or GST-ERb was incubated with
purified His-CTGF or His-Nov. As shown in Fig. 2D, CTGF, but
not Nov, another CCN family member, directly interacted with
ERa and ERb.
Mapping of the ER and CTGF interaction regions
ERa DBD was shown to interact specifically with CTGF in the
yeast two-hybrid system (Fig. 1C). To further confirm the region of
ERa required for its interaction with CTGF, GST pull-down
experiments were performed in which GST-ERa(180–282)
containing the DBD, and GST were incubated with purified
His-tagged CTGF. Consistent with the results of the yeast two-
hybrid, the direct interaction of CTGF with ERa DBD was also
observed in the GST pull-down assay (Fig. 3A).
To define which domain of CTGF interacts with ER, GST pull-
down experiments were performed again. The CTGF(182–349)
fragment containing the TSP-1 and CT domains bound
specifically to ERa and ERb, whereas the CTGF(27–187)
fragment containing the IGFBP and VWC domains but lacking
the signal peptide did not bind ERa and ERb (Fig. 3B, left panel).
Further deletion analysis showed that the CTGF(182–250)
containing the TSP-1 domain, but not the CTGF(244–349)
containing the CT domain, is sufficient for ER binding (Fig. 3B,
right panel). Compared with the results in Fig. 2, the CTGF(182–
349) fragment interacted with ERb very weakly. This might be
due to different fusion proteins used and conformational changes
in the fusion proteins.
Overexpression of CTGF inhibits the transcriptional
activity of ERa and ERb
Having firmly established that CTGF is an ERa- and ERb-
binding protein, we tested the effect of CTGF overexpression on
the transcriptional activity of ERa and ERb.E R a- and ERb-
positive MCF7 cells were cotransfected with the reporters, ERE-
Luc (an artificial estrogen-responsive element-containing reporter)
or pS2-Luc (a natural pS2 promoter-containing reporter), and
Figure 3. Mapping of the ERa and CTGF interaction domains. (A) Direct interaction of ERa DBD with CTGF. GST or GST-ERa(180–282) was
incubated with purified His-CTGF. Bound proteins were analyzed as described in the legend to Figure 2D. (B) Mapping of the ER interaction region in
CTGF.
35S-labelled in vitro translated ER was incubated with GST-CTGF(27–187), GST-CTGF(182–349), GST-CTGF(182–250) or GST-CTGF(244–349), or
with GST. The bound proteins were subjected to SDS-PAGE followed by autoradiography. Also shown are schematic diagrams of the constructs used
in this study.
doi:10.1371/journal.pone.0020028.g003
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20028Figure 4. CTGF regulates estrogen-responsive reporter activity. (A–C) MCF7 cells were cotransfected with ERE-Luc (A and C) or pS2-Luc (B)
reporter, and increasing amounts of plasmid expressing FLAG-tagged CTGF (A and B) or the indicated amounts of recombinant human (rh) CTGF, EGF
or IGF-1 proteins (C). Cells were treated with or without 10 nm E2 for 24 h and analyzed for luciferase activity. Data shown are means 6 SD of
triplicates of one representative experiment and have been repeated three times with similar results.
#P,0.05 versus empty vector without E2.
*P,0.01 versus empty vector without E2.
$P,0.05 versus empty vector with E2.
%P,0.01 versus empty vector with E2. (D) Hela cells were co-
transfected with ERE-Luc, FLAG-tagged CTGF, and ERa or ERb as indicated. Cells were treated and analyzed as in (A–C). *P,0.01 versus ERa
expression vector without E2.
$P,0.01 versus ERa expression vector with E2.
#P,0.01 versus ERb expression vector without E2.
%P,0.01 versus ERb
expression vector with E2. (E) Hela cells were transfected with expression vector for CTGF siRNA1, CTGF siRNA2 or scramble siRNA (control) plasmid.
Cells were harvested and lysed, and conditioned medium was concentrated using a 10-kDa membrane. Both the concentrate and the cell lysate were
used for immunoblotting of the expression of CTGF, and the whole cell lysate was used for immunoblotting of the expression of GAPDH. (F) Hela cells
were cotransfected with ERE-Luc, ERa or ERb, and CTGF siRNA1 or CTGF siRNA2, as indicated. Cells were treated and analyzed as in (A–C).
#P,0.05
versus ERa expression vector without E2. *P,0.05 versus ERa expression vector with E2.
$P,0.01 versus ERa expression vector with E2.
@P,0.05
versus ERb expression vector without E2.
%P,0.05 versus ERb expression vector with E2.
&P,0.01 versus ERb expression vector with E2.
doi:10.1371/journal.pone.0020028.g004
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stimulated the endogenous ERa- and ERb-mediated transcrip-
tional activity (Fig. 4 A and B). Importantly, in both the presence
and the absence of E2, overexpression of CTGF decreased both
reporter activities in a dose-dependent manner. Similar results
were observed in the ZR75-1 cell line, another human ERa-
positive breast cancer cell line (data not shown, but see below).
Moreover, recombinant human CTGF protein at similar levels to
CTGF physiological concentrations in MCF7 cells also decreased
the ERE-Luc activity, whereas recombinant EGF and IGF-1
proteins increased the ERE-Luc activity as previously reported
[6,7] (Fig. 4C).
To exactly determine the effect of CTGF overexpression on the
transcriptional activity of ERa and ERb,E R a- and ERb-negative
human Hela cervical cancer cells were cotransfected with the
ERE-Luc reporter, ERa or ERb, and FLAG-tagged CTGF. As
shown in Fig. 4D, CTGF overexpression inhibited both ERa- and
ERb-dependent ERE-Luc reporter activities.
To test whether CTGF is a general repressor of nuclear receptor
action, the effects of CTGF on the transcriptional activities of
other nuclear receptors, such as androgen receptor (AR) and
glucocorticoid receptor (GR), were investigated. MCF7 cells were
cotransfected with FLAG-tagged CTGF and the ARE-Luc
(androgen-responsive element-containing luciferase reporter) or
pFC31-Luc (glucocorticoid-responsive element-containing lucifer-
ase reporter) reporter. As expected, R1881, a synthetic androgen,
stimulated endogenous AR-mediated transcriptional activity (Fig.
S2A), and dexamethasone (Dex), a synthetic gulcocorticoid,
activated endogenous GR-mediated transcriptional activity (Fig.
S2B). However, CTGF had no effect on transactivation function of
both AR and GR, suggesting that CTGF specifically regulates ER
transcriptional activity.
Knockdown of endogenous CTGF increases the
transcriptional activity of ERa and ERb
To investigate the role of endogenous CTGF in regulation of
ERa- and ERb-mediated transcriptional activity, Hela cells, which
expressed high level of CTGF, were transfected with vector-based
CTGF siRNAs or universal scramble siRNA (control). As shown in
Fig. 4E, CTGF siRNA1 and CTGF siRNA2 effectively repressed
the expression of CTGF to varying degrees, whereas universal
scramble siRNA had no effect. In agreement with the inhibitory
effects of both CTGF siRNAs, suppression of the normal
expression of CTGF in Hela cells by the specific CTGF siRNAs
significantly increased the ERa-o rE R b-mediated ERE-Luc
reporter activity (Fig. 4F). These results further suggest that CTGF
decreases the transcriptional activity of ERa and ERb.
CTGF decreases the expression of endogenous estrogen-
responsive genes
To corroborate the results of the luciferase reporter assays, the
effect of CTGF on the expression of endogenous estrogen-
responsive genes was examined. The E2-deprived MCF-7 cells
stably expressing either the empty vector or FLAG-tagged CTGF
were treated with 10 nM E2 for 20 h. As expected, E2 increased
the expression of two well-studied estrogen-responsive genes [3],
pS2 and cathepsin D, in the empty vector-transfected cells (Fig. 5).
Importantly, the transfection of CTGF decreased the expression of
pS2 and cathepsin D both in the absence and in the presence of
E2. These data suggest that CTGF represses the expression of
endogenous ERa-responsive genes.
Secreted CTGF is critical for repression of ER
transcriptional activity
As CTGF is a secreted protein, we used the constructs for wild-
type CTGF and CTGF without the signal peptide to test if CTGF
regulates ER transcriptional activity through autocrine and/or
paracrine mechanisms. ERa-positive ZR75-1 cells were transfect-
ed with the constructs for FLAG-tagged CTGF or CTGF without
the signal peptide [CTGF(D1-26)]. Unlike FLAG-tagged CTGF,
CTGF(D1-26) could not be secreted into medium (data not
shown). ZR75-1 cells were then cotransfected with the ERE-Luc
reporter and FLAG-tagged CTGF or CTGF(D1-26). As shown in
Fig. 6A, CTGF markedly inhibited the reporter activity, whereas
CTGF(D1-26) abrogated the ability of CTGF to repress the
activity. It should be noted that FLAG-tagged CTGF and
CTGF(D1-26) were expressed at comparable levels (Fig. 6B).
These data suggest that secreted CTGF, but not cytoplasmic
CTGF, is responsible for repression of ER transcriptional activity.
The interaction of CTGF and ER is required for repression
of estrogen-responsive transcription
To examine whether the interaction between CTGF and ER is
necessary for the regulation of estrogen-responsive transcription,
the CTGF mutant [CTGF(1–187)] which failed to interact with
ER was used. MCF7 cells were cotransfected with the ERE-Luc
reporter and FLAG-tagged full-length CTGF or CTGF(1–187).
As shown in Fig. 6C, the CTGF(1–187) lacking the ER-binding
site completely abolished the CTGF repression of the reporter
activity. In contrast, the CTGF(1–187) slightly increased the
reporter activity. Notably, both FLAG-tagged CTGF and
CTGF(1–187) could be secreted into medium and were expressed
at comparable levels (Fig. 6D). These data suggest that the
interaction between CTGF and ER is required for repression of
estrogen-responsive transcription by CTGF.
CTGF did not affect ERa binding to ERE sequence
To investigate molecular mechanism by which CTGF modu-
lates ER transcriptional activity, the effect of CTGF on ERa
binding to ERE sequence was determined by EMSA. As expected,
the biotin-labeled ERE, but not mutant ERE (EREM), bound to
proteins from ER-positive ZR75-1 nuclear extracts in the presence
of E2 (Fig. 7). The binding was specifically inhibited by a 100-fold
molar excess of a cold ERE oligonucleotide. The addition of
human anti-ERa antibody to the reaction caused a supershift,
indicating that ERa protein from ZR75-1 nuclear extracts
specifically binds to ERE sequence. However, overexpression of
Figure 5. CTGF reduces estrogen-responsive protein expres-
sion. MCF7 cells stably transfected with FLAG-tagged CTGF were
treated with E2 or without E2. Conditioned media were blotted with
antibodies to cathepsin D (CatD), pS2 and FLAG, and whole cell lysates
were blotted with anti-GAPDH.
doi:10.1371/journal.pone.0020028.g005
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suggesting the involvement of other mechanism(s) in CTGF
modulation of ER transcriptional activity.
CTGF inhibits ERa expression
To further investigate the mechanisms by which CTGF
represses ER transcriptional activity, we determined the effect of
CTGF on ERa expression by immunoblotting. As expected [18],
E2 decreased ERa protein levels in MCF7 or ZR75-1 cells (Fig. 8
A–E). Importantly, Both FLAG-tagged CTGF and recombinant
human CTGF inhibited ERa protein expression both in the
presence and in the absence of estrogen, and recombinant human
CTGF inhibited ERa protein expression in a dose-dependent
manner (Fig. 8 A, B and D). In contrast, knockdown of
endogenous CTGF in MCF7 or ZR75-1 cells increased ERa
protein levels (Fig. 8 C and E). Although FLAG-tagged full-length
CTGF repressed the expression of ERa protein, the CTGF(1–187)
mutant that did not decrease ERa transcriptional activity also did
not change ERa protein levels in MCF7 cells (Fig. 8F). Reduction
of ERa protein levels by CTGF is not mediated through
proteosome-dependent protein degradation because MG132, a
proteosome inhibitor, had no effect on CTGF-mediated repression
of ERa protein expression (Fig. 8G). As a control, MG132 blocked
E2-induced dowregulation of ERa.
Next, we investigated the effect of CTGF on ERa mRNA
expression. As previously reported [19], E2 decreased ERa
mRNA levels in MCF7 cells (Fig. 8H and Fig. S3). Intriguingly,
CTGF reduced ERa mRNA expression both in the presence and
in the absence of estrogen, whereas the CTGF(1–187) mutant that
did not repress ERa transcriptional activity also did not alter ERa
mRNA levels in MCF7 cells. Taken together, these results suggest
that CTGF may regulate ERa expression at the mRNA level and
that CTGF inhibits ERa transcriptional activity at least in part
through decreased ERa expression.
Discussion
Estrogen plays a critical role in regulating the growth,
differentiation, and function of tissues of the reproductive system,
including the mammary glands, uterus, vagina, and ovaries in
females, and the testis, epididymis, and prostate in males. Estrogen
exerts its biological function through ERs acting via classical
genomic events in the nucleus and by non-genomic actions at the
Figure 6. Effects of CTGF deletion mutants on estrogen-responsive reporter activity. (A) Luciferase reporter assay with the CTGF deletion
mutant without the signal peptide. ZR75-1 cells were cotransfected with ERE-Luc and FLAG-tagged CTGF or CTGF(D1-26) as indicated. Cells were
treated and analyzed as in Fig. 4A. *P,0.01 versus empty vector without E2.
#P,0.01 versus empty vector with E2. (B) Western blotting showing
expression levels of FLAG-tagged CTGF and CTGF(D1-26) with antibody against FLAG or GAPDH. Cells were transfected in the presence of E2 as in (A).
(C) Luciferase reporter assay with the CTGF deletion mutant lacking ER-binding site. Cells were cotransfected with ERE-Luc and FLAG-tagged CTGF or
CTGF(1–187) as indicated. *P,0.01 versus empty vector without E2.
#P,0.05 versus empty vector with E2.
$P,0.01 versus empty vector with E2. (D)
Western blotting showing expression levels of FLAG-tagged CTGF and CTGF(1–187) with antibody against FLAG or GAPDH. Cells were transfected in
the presence of E2 as in (C). Conditioned medium was used for Western blotting analysis of the expression of FLAG-tagged CTGF and CTGF(1–187),
and the whole cell lysate was used for Western blotting analysis of the expression of GAPDH.
doi:10.1371/journal.pone.0020028.g006
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ERs remains to be characterized, increasing evidence indicates
that the non-genomic actions of estrogen involve the classical ERs
located at the plasma membrane [21–23]. Membrane ERa
mediates non-genomic estrogen actions by forming a complex
with many signaling molecules, such as the regulatory subunit of
phosphatidylinositol-3-OH kinase (PI3K), Shc, IGF-1R, SRC, and
caveolin-1, leading to indirect activation of ER transcriptional
activity.
ER genomic activity is also enhanced by various growth factor
signaling pathways, such as EGF, IGF-1 and transforming growth
factor a (TGFa) [6,7]. These peptide growth factors, which are
extracellular ligands, induce transcriptional activation of a
concensus estrogen response element (ERE) in an ER-dependent
manner in various cell types, including breast cancer and ovarian
cancer cell lines. The growth factors and estrogen synergistically
enhance ER transactivation function although there is no
synergism between the different classes of growth factors, such as
TGFa and IGF-1. Unlike EGF and IGF-1, which increases ER
transcriptional activity, CTGF, another growth factor, represses
ER transcriptional activity both in the presence and in the absence
of estrogen. To the best of our knowledge, CTGF is the first
growth factor to inhibit ER transcriptional activation.
IGF-1R has been shown to physically interact with ER after
estrogen treatment [24]. Since IGF-1 is a ligand for IGF-1R, it is
possible that IGF-1 increases ER transcriptional activity through
its interaction with IGF-1R. Whether IGF-1, IGF-1R and ER
form a complex remains to be elucidated. In this study, we present
evidence of physical and functional interactions between CTGF
and ER. The physical interaction has been validated by a number
of in vitro and in vivo experiments, including yeast two-hybrid, in
vitro GST pull-down, in vivo co-immunoprecipitation, ELISA,
and immunofluorescence. Importantly, CTGF directly associates
with ER. Moreover, we can demonstrate that CTGF functionally
inhibits ER transcriptional activity, suggesting that CTGF is a
novel repressor of ER signaling. Secreted CTGF, but not
cytoplasmic CTGF, is critical for repression of ER transcriptional
activity. Secreted wild-type CTGF that interacts with ER can
repress ER transcriptional activity, whereas the secreted CTGF
mutant that fails to interact with ER also fails to inhibit ER
transcriptional activity. We believe that CTGF is the first molecule
of this class to be identified, but most likely there will be more to
come. This notion may be supported by the fact that membrane
ER activates multiple intracellular signaling pathways and peptide
growth factors cross-talk with ER signaling [4,5,25].
The ERa-interacting region in CTGF is mapped to the
thrombospondin type I repeat (TSP-1), which is thought to be a
cell attachment motif [8–10]. CTGF interacts with ERa DNA-
binding domain (DBD). ERa has been reported to interact with a
number of co-factors, including co-activators and co-repressors
[26,27]. Most of ERa co-factors interact with ERa ligand-binding
domain (LBD), whereas very few ERa co-factors interact with the
DBD. The ERa DBD-interacting proteins include the co-activator
X box-binding protein 1 (XBP-1) [13], which regulates ERa
signaling both in the absence and in the presence of estrogen, and
the co-repressors template-activating factor Ib (TAF-Ib) [28], pp32
[29], and zinc finger protein 366 (ZNF366) [30]. Like these co-
repressors, CTGF inhibits ERa transcriptional activity. Since the
DBD domain of ERa has 96% homology with that of ERb,i ti s
not surprising that both ERa and ERb bind to CTGF.
It has been reported that integrins anb3, aIIbb3, aMb2 and
a5b1, and low density lipoprotein receptor-related protein/a2-
macroglobulin receptor (LRP) are cell surface receptors of CTGF
[31,32]. Through binding to these cell surface proteins, CTGF
exerts a range of diverse biological functions, including prolifer-
ation, differentiation, apoptosis, cell adhesion, migration, and
angiogenesis. CTGF interacts with the Wnt receptor complex,
including the Wnt receptor Frizzled 8 and the Wnt co-receptor
LRP6, and inhibits Wnt signaling, which is pivotal to gene
expression, cell adhesion, tissue development and oncogenesis
[33]. The C-terminal (CT) domain of CTGF, which is not
necessary for binding ER, is required for binding LRP6 and
complete inhibition of Wnt signaling by CTGF. There are at least
19 Wnt family members that signal through complexes comprising
the Frizzled family of cell surface receptors together with LRP
family members, which serve as co-receptors. Several lines of
evidence demonstrated cross-talk between Wnt and estrogen
signaling pathways [34–37]. Both Cyclin D1 and c-Myc,
important regulators of cell proliferation, are known targets for
both Wnt and estrogen pathways [35]. Estrogen rapidly increases
the expression of Wnt-4 and Wnt-5a of the Wnt family and
frizzled 2 of the Wnt receptor in the mouse uterus in an ER-
independent manner, and the estrogen-dependent control of Wnt
signaling then regulates late uterine growth response that is ER
dependent [36]. Interestingly, ERa expression was restored at
both mRNA and protein level after treatment of ERa-negative
breast cancer cells with Wnt-5a [37]. Whether CTGF integrates
estrogen and Wnt signaling remains to be investigated.
Several lines of evidence support important roles for CTGF in
cancer development and progression. Over-expression of CTGF is
found in prostate cancers [38], gliomas [39] and esophageal
Figure 7. Effect of CTGF on ERa binding to ERE sequence. EMSA
was performed using biotin-labeled ERE probe and nuclear proteins
extracted from ZR75-1 cells transfected with empty vector or FLAG-
tagged CTGF in the presence of 10 nM E2. For competition
experiments, a 100-fold molar excess of unlabeled ERE was incubated
with the labeled probe. The biotin-labeled mutant ERE probe (EREM)
was used as a negative control. Supershifts were performed using
specific anti-ERa antibody. The representative immunoblot with anti-
FLAG shows the expression level of intracellular FLAG-tagged CTGF
(lower panel).
doi:10.1371/journal.pone.0020028.g007
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20028Figure 8. CTGF inhibits ERa expression. (A) MCF7 cells stably transfected with FLAG-tagged CTGF, which constitutively expressed FLAG-CTGF, or
MCF7 cells stably transfected with empty vector were treated with 10 nm E2 for 24 h. Whole cell lysates were blotted with the indicated antibodies.
(B) MCF7 cells were treated with the indicated amounts of recombinant human CTGF (rhCTGF) and analyzed as in (A). (C) MCF7 cells transfected with
CTGF siRNA2 or control siRNA were treated and analyzed as in (A). Knockdown effect of CTGF siRNA2 on the endogenous CTGF mRNA level was
determined by real-time PCR with CTGF and b-actin primers (right panel). (D) ZR75-1 cells transiently transfected with FLAG-tagged CTGF or empty
vector were treated and analyzed as in (A). (E) ZR75-1 cells transfected with CTGF siRNA1 or CTGF siRNA2 were treated and analyzed as in (A).
Knockdown effect of CTGF siRNA1 or CTGF siRNA2 on the endogenous CTGF mRNA levels was determined as in (C) (lower panel). (F) MCF7 cells were
transfected with FLAG-tagged CTGF or CTGF(1–187) and treated with 10 nm E2. Cell lysates were analyzed by immunoblot with the indicated
antibodies. (G) MCF7 cells stably transfected with FLAG-tagged CTGF or empty vector were pretreated with 10 mM MG132 for 1 h to block
proteasome activity. Cells were then treated with 10 nM E2 for 24 h. Cell lysates were analyzed as in (D). (H) MCF7 cells transfected with FLAG-tagged
CTGF or CTGF(1–187) were used for real-time RT-PCR with ERa and GAPDH primers (upper panel). Cell lysates were examined by immunoblot with
the indicated antibodies (lower panel). Data shown are means 6 SD of triplicates of one representative experiment and have been repeated three
times with similar results. *P,0.01 versus empty vector without E2.
#P,0.01 versus empty vector with E2.
doi:10.1371/journal.pone.0020028.g008
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proliferation as well as tumorigenecity. In sharp contrast, CTGF
expression is down-regulated in lung [41], colon [42] and ovarian
[43] cancers. Over-expression of CTGF inhibits the growth of
ovarian cancer cells as well as invasion and metastasis of lung and
colon cancer cells in vitro and in vivo. Taken together, these data
suggest that the role of CTGF in cancer development and
progression is dependent on cancer or cell types. Contradictory
results have been reported on the role of CTGF in breast cancer.
Jiang et al. showed that, in addition to lower levels of CTGF in
breast cancer tissues (122 cases) compared with normal tissues (32
cases), markedly reduced levels of CTGF in breast cancer patients
are associated with poor prognosis, metastasis, local recurrence
and mortality [44], whereas Xie et al. demonstrated that,
compared with normal breast (7 cases), elevated levels of CTGF
in primary breast cancer (44 cases) was observed [45]. Several
studies about the effects of CTGF on breast cancer cell growth,
migration and metastasis also produced conflicting results. The
study by Hishikawa showed that forced expression of CTGF in
MCF7 breast cancer cells stimulates apoptosis [46]. However,
Chen et al. reported that CTGF increases the motility of breast
cancer cells [31]. Another study by Kang et al. indicated that over-
expression of CTGF alone in human breast cancer MDA-MB-231
cells did not cause a significant increase in bone metastasis
formation, whereas over-expression of CTGF together with
interleukin-11 (IL-11) and osteopontin (OPN) showed a dramatic
increase both in the rate and in the incidence of bone metastases
[47]. A recent study demonstrated that over-expression of the
genome organizer protein SATB1, which is over-expressed in
aggressive breast tumors, stimulates CTGF expression [48]. TGF-
b, a cytokine that inhibits growth of normal epithelia and early
stage tumors but stimulates invasion and metastasis of aggressive
tumors, also increases CTGF expression. It is unclear whether
CTGF has dual effects like TGF-b. Therefore, it will be interesting
to determine the biological significance of CTGF repression of ER
transcriptional activity in cancer development and progression.
The fact that CTGF can inhibit ERa expression in breast
cancer cell lines suggests that ERa-negative breast cancers might
have high levels of CTGF, whereas ERa-positive breast cancers
might have low levels. Jiang et al. showed that, although there was
no significant correlation between ERa and CTGF when breast
tumors were analyzed as an entire cohort, ERa was inversely
correlated with CTGF in tumor-node-metastasis (TNM) 3 breast
tumors [44]. Generally speaking, the TNM 3 breast cancer group
is more aggressive than TNM groups 1 and 2. It has been reported
that ERa-positive breast cancers are often responsive to anti-
estrogen therapy and generally have a better prognosis, while
ERa-negative breast cancers are more aggressive and unrespon-
sive to anti-estrogens [1]. Our present findings raise the possibility
that, at least in a subset of breast cancer patients, CTGF might
contribute to the process of breast cancer progression by allowing
the development of ERa-negative phenotypes through reduction
of ERa expression and repression of ER transcriptional activity,
resulting in enhanced aggressiveness of breast cancer cells. Large
clinical samples are needed to exactly elucidate the correlation of
CTGF with ERa in breast cancer.
Supporting Information
Figure S1 Characterization of anti-CTGF antibody for
Immunofluorescence. (A) Anti-CTGF was pre-incubated with
His control or approximately 10 mg of His-tagged CTGF protein
(His-CTGF) for 1 h and then used for immunofluorescence
analysis of MCF7 cells stably transfected with FLAG-tagged
CTGF. The nuclei were stained with DAPI. The CTGF
expression was visualized by fluorescence microscopy (Left panel).
Original magnification, 6200. Scale bar, 50 mm. SDS-PAGE
analysis of the purified His-CTGF protein is shown in the right
panel. (B) MCF7 cells or MCF7 cells stably transfected with
FLAG-tagged CTGF were stained with the anti-CTGF antibody
and analyzed as in (A).
(TIF)
Figure S2 Effect of CTGF on the transcriptional activ-
ities of AR and GR. MCF7 cells were cotransfected with FLAG-
tagged CTGF and the ARE-Luc (A) or pFC31-Luc (B) reporter.
Cells were treated with or without 0.1 nm R1881 or 0.1 mM Dex
for 24 h and analyzed for luciferase activity. Data shown are
means 6 SD of triplicates of one representative experiment and
have been repeated three times with similar results.
(TIF)
Figure S3 CTGF suppresses ERa mRNA expression.
MCF7 cells were transfected with FLAG-tagged CTGF or
CTGF(1–187) as in Figure 8 and were used for real-time RT-
PCR with ERa and b-actin primers. Data shown are means 6 SD
of triplicates of one representative experiment and have been
repeated three times with similar results. *P,0.01 versus empty
vector without E2.
#P,0.01 versus empty vector with E2.
(TIF)
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